AIMS/HYPOTHESIS: Raised N-terminal pro-B-type natriuretic peptide (NT-proBNP) is associated with a poor cardiac outcome in non-diabetic populations. Elevated NT-proBNP predicts excess morbidity and mortality in diabetic patients with an elevated urinary albumin excretion rate. This study investigated the prognostic value of NT-proBNP in a cohort of type 2 diabetic patients. SUBJECTS, MATERIALS AND METHODS: In a prospective observational follow-up study, 315 type 2 diabetic patients with normoalbuminuria (n=188), microalbuminuria (n=80) and macroalbuminuria (n=47) at baseline were followed for a median (range) of 15.5 (0.2-17.0) years. Plasma NT-proBNP concentrations were determined by immunoassay at baseline. Endpoints were overall and cardiovascular mortality. RESULTS: Of the patients, 162 died (51%), 119 of them (74%) due to cardiovascular causes. All-cause mortality was increased in patients with NT-proBNP in the second and third tertiles (hazard ratios [95% CI] compared with the first tertile, 1.70 [1.08-2.67] and 5.19 [3.43-7.88], p<0.001). These associations persisted after adjustment for urinary albumin excretion rate, glomerular filtration rate and conventional cardiovascular risk factors (covariate adjusted hazard ratios 1.46 [0.91-2.33] and 2.54 [1.56-4.14], p<0.001). This increased mortality was attributable to more cardiovascular deaths in the second and third NT-proBNP tertile (unadjusted hazard ratios 1.63 [0.96-2.77] and 4.88 [3.01-7.91], p<0.001; covariate adjusted 1.37 [0.79-2.37] and 2.26 [1.27-4.02], p=0.01). When patients with normo-, micro- and macroalbuminuria were analysed separately, NT-proBNP levels above the median (62 ng/l) were consistently associated with increased overall and cardiovascular mortality in all three groups (p<0.001). CONCLUSIONS/ INTERPRETATION: In patients with type 2 diabetes, elevated circulating NT-proBNP is a strong predictor of the excess overall and cardiovascular mortality, this predictor status being independent of urinary albumin excretion rate and conventional cardiovascular risk factors.
AIMS/HYPOTHESIS: Raised N-terminal pro-B-type natriuretic peptide (NT-proBNP) is associated with a poor cardiac outcome in non-diabetic populations. Elevated NT-proBNP predicts excess morbidity and mortality in diabeticpatients with an elevated urinary albumin excretion rate. This study investigated the prognostic value of NT-proBNP in a cohort of type 2 diabeticpatients. SUBJECTS, MATERIALS AND METHODS: In a prospective observational follow-up study, 315 type 2 diabeticpatients with normoalbuminuria (n=188), microalbuminuria (n=80) and macroalbuminuria (n=47) at baseline were followed for a median (range) of 15.5 (0.2-17.0) years. Plasma NT-proBNP concentrations were determined by immunoassay at baseline. Endpoints were overall and cardiovascular mortality. RESULTS: Of the patients, 162 died (51%), 119 of them (74%) due to cardiovascular causes. All-cause mortality was increased in patients with NT-proBNP in the second and third tertiles (hazard ratios [95% CI] compared with the first tertile, 1.70 [1.08-2.67] and 5.19 [3.43-7.88], p<0.001). These associations persisted after adjustment for urinary albumin excretion rate, glomerular filtration rate and conventional cardiovascular risk factors (covariate adjusted hazard ratios 1.46 [0.91-2.33] and 2.54 [1.56-4.14], p<0.001). This increased mortality was attributable to more cardiovascular deaths in the second and third NT-proBNP tertile (unadjusted hazard ratios 1.63 [0.96-2.77] and 4.88 [3.01-7.91], p<0.001; covariate adjusted 1.37 [0.79-2.37] and 2.26 [1.27-4.02], p=0.01). When patients with normo-, micro- and macroalbuminuria were analysed separately, NT-proBNP levels above the median (62 ng/l) were consistently associated with increased overall and cardiovascular mortality in all three groups (p<0.001). CONCLUSIONS/ INTERPRETATION: In patients with type 2 diabetes, elevated circulating NT-proBNP is a strong predictor of the excess overall and cardiovascular mortality, this predictor status being independent of urinary albumin excretion rate and conventional cardiovascular risk factors.
Authors: C E Mogensen; W F Keane; P H Bennett; G Jerums; H H Parving; P Passa; M W Steffes; G E Striker; G C Viberti Journal: Lancet Date: 1995-10-21 Impact factor: 79.321
Authors: Alan H B Wu; Torbjørn Omland; Philippe Duc; James McCord; Richard M Nowak; Judd E Hollander; Howard C Herrmann; Philippe G Steg; Cathrine Wold Knudsen; Alan B Storrow; William T Abraham; Alberto Perez; Richard Kamin; Paul Clopton; Alan S Maisel; Peter A McCullough Journal: Diabetes Care Date: 2004-10 Impact factor: 19.112
Authors: Margaret M Redfield; Richard J Rodeheffer; Steven J Jacobsen; Douglas W Mahoney; Kent R Bailey; John C Burnett Journal: Circulation Date: 2004-06-07 Impact factor: 29.690
Authors: Claire Sweeney; Fiona Ryan; Mark Ledwidge; Cristin Ryan; Ken McDonald; Chris Watson; Rebabonye B Pharithi; Joe Gallagher Journal: Cochrane Database Syst Rev Date: 2019-10-15
Authors: Emilie H Zobel; Bernt Johan von Scholten; Henrik Reinhard; Frederik Persson; Tine W Hansen; Hans-Henrik Parving; Peter K Jacobsen; Peter Rossing Journal: Diabetologia Date: 2017-07-05 Impact factor: 10.122
Authors: F I Fringu; A V Sitar-Taut; B Caloian; D Zdrenghea; D Comsa; G Gusetu; D Pop Journal: Acta Endocrinol (Buchar) Date: 2020 Apr-Jun Impact factor: 0.877
Authors: Erika F Brutsaert; Mary L Biggs; Joseph A Delaney; Luc Djoussé; John S Gottdiener; Joachim H Ix; Francis Kim; Kenneth J Mukamal; David S Siscovick; Russell P Tracy; Ian H de Boer; Christopher R deFilippi; Jorge R Kizer Journal: Metabolism Date: 2016-06-24 Impact factor: 8.694
Authors: Henrik Reinhard; Maria Lajer; Mari-Anne Gall; Lise Tarnow; Hans-Henrik Parving; Lars M Rasmussen; Peter Rossing Journal: Diabetes Care Date: 2010-10-07 Impact factor: 19.112